Pioglitazone for Reducing Sympathetic Overactivity in CKD Patients via ADMA Reduction

Chronic Kidney Disease (CKD) affects over 26 million Americans, with more patients dying from cardiovascular complications than those progressing to dialysis. One of the key risk factors is an overactive sympathetic nervous system, which can contribute to high blood pressure and accelerate organ damage. Despite standard treatments, this issue remains unresolved. This study focuses on a potential cause of this overactivity - a substance called asymmetric dimethylarginine (ADMA) that accumulates in CKD patients. ADMA is a strong predictor of future cardiovascular events. The study aims to investigate if a drug called pioglitazone can reduce ADMA levels, potentially improving cardiovascular outcomes in CKD patients. In this study, participants with CKD will receive pioglitazone treatment for one month. The primary outcome measured is the change in muscle sympathetic nerve activity (MSNA), an indicator of sympathetic nervous system activity. This will be recorded using standard microneurographic techniques, involving the insertion of a tiny electrode into the peroneal nerve near the fibular head of the leg. The signals from the nerve will be amplified, filtered, and integrated to obtain mean voltage neurograms. The study hypothesizes that pioglitazone treatment will lower ADMA levels and subsequently reduce MSNA, potentially leading to improved cardiovascular health in CKD patients.